StockData
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. (VERA) stock

VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$25.58−0.62 (-2.37%)

Close on Nov 18, 2026Market cap $1.84BP/E –Yield –

Vera Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vera Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$415.76M. For fiscal 2025 it was -$315.47M. The highest annual figure on record is -$34.40M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$315.47M–
FY2024Dec 31, 2024-$167.17M–
FY2023Dec 31, 2023-$102.01M–
FY2022Dec 31, 2022-$90.90M–
FY2021Dec 31, 2021-$34.40M–
FY2020Dec 31, 2020-$52.24M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$112.49M–
Q1 FY2026Mar 31, 2026-$125.13M–
Q4 FY2025Dec 31, 2025-$94.21M–
Q3 FY2025Sep 30, 2025-$83.93M–
Q2 FY2025Jun 30, 2025-$80.14M–
Q1 FY2025Mar 31, 2025-$57.19M–
Q4 FY2024Dec 31, 2024-$48.91M–
Q3 FY2024Sep 30, 2024-$49.80M–
Q2 FY2024Jun 30, 2024-$37.34M–
Q1 FY2024Mar 31, 2024-$31.11M–
Q4 FY2023Dec 31, 2023-$27.03M–
Q3 FY2023Sep 30, 2023-$21.76M–
Q2 FY2023Jun 30, 2023-$21.97M–
Q1 FY2023Mar 31, 2023-$31.26M–
Q4 FY2022Dec 31, 2022-$33.58M–
Q3 FY2022Sep 30, 2022-$25.24M–
Q2 FY2022Jun 30, 2022-$15.06M–
Q1 FY2022Mar 31, 2022-$17.02M–
Q4 FY2021Dec 31, 2021-$16.59M–
Q3 FY2021Sep 30, 2021-$7.25M–
Q2 FY2021Jun 30, 2021-$5.85M–
Q1 FY2021Mar 31, 2021-$4.72M–
Q4 FY2020Dec 31, 2020-$42.56M–
Q3 FY2020Sep 30, 2020-$4.04M–
Q2 FY2020Jun 30, 2020-$3.17M–
Q1 FY2020Mar 31, 2020-$2.47M–

More Vera Therapeutics figures

See a number that looks wrong?